Invention: EEG-based monitoring of rapid acting antidepressant actions.
IP Status: Patent pending.
Project status: Preclinical PoC studies completed, planning of the first clinical trial ongoing.
Major depression is a highly disabling psychiatric condition, the most significant risk factor for suicide and one of the biggest contributors to the disease burden worldwide. Depression affects an estimated one in every 15 adults and at global level, over 300 million people are estimated to suffer from depression. Depressive disorders produce immeasurable human suffering and enormous economic burden. In the US alone, the economic burden caused by depression exceeds $ 200 billion. Depressed mood, anhedonia, lack of concentration, feelings of worthlessness and suicidal thoughts are common symptoms of depression. Traditional antidepressants take weeks to reduce these depressive symptoms, while some patients do not respond at all. Rapid-acting antidepressants produce immediate relief for many, but we lack the understanding to monitor treatment efficacy and to develop new treatments.
Faculty of Biological and Environmental Sciences, University of Helsinki